每經(jing)AI快訊(xun)，泰恩康（SZ 301263，收盤(pan)價：18.2元(yuan)）8月29日發布公(gong)(gong)(gong)(gong)告稱，廣東(dong)泰恩康醫藥(yao)股(gu)(gu)(gu)份(fen)有限(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)根據控股(gu)(gu)(gu)子公(gong)(gong)(gong)(gong)司(si)(si)(si)江蘇博(bo)創(chuang)(chuang)園生(sheng)物(wu)醫藥(yao)科(ke)技有限(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)的發展需要，公(gong)(gong)(gong)(gong)司(si)(si)(si)與博(bo)創(chuang)(chuang)園及(ji)其(qi)少數股(gu)(gu)(gu)東(dong)簽署了《關于江蘇博(bo)創(chuang)(chuang)園生(sheng)物(wu)醫藥(yao)科(ke)技有限(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)之增資(zi)(zi)協(xie)議》，公(gong)(gong)(gong)(gong)司(si)(si)(si)擬以自有或自籌資(zi)(zi)金出(chu)資(zi)(zi)人民(min)幣1.5億元(yuan)對博(bo)創(chuang)(chuang)園進行(xing)增資(zi)(zi)，其(qi)中998.63萬元(yuan)計(ji)入(ru)注冊(ce)資(zi)(zi)本(ben)，約1.4億元(yuan)計(ji)入(ru)資(zi)(zi)本(ben)公(gong)(gong)(gong)(gong)積(ji)，增資(zi)(zi)完成后(hou)公(gong)(gong)(gong)(gong)司(si)(si)(si)將持有博(bo)創(chuang)(chuang)園約60.73%股(gu)(gu)(gu)權。博(bo)創(chuang)(chuang)園少數股(gu)(gu)(gu)東(dong)均(jun)自愿放棄本(ben)次新增注冊(ce)資(zi)(zi)本(ben)的優先認購權。

2022年1至12月份，泰恩康的營業收入(ru)構(gou)成(cheng)為(wei)：醫藥代理占比(bi)49.49%，醫藥制造占比(bi)46.06%，醫藥技術服務占比(bi)4.36%。

泰(tai)恩康的董(dong)事(shi)長、總經理(li)均是鄭漢杰(jie)，男，60歲，學(xue)歷(li)背景為碩士。

道達號（daoda1997）“個股趨勢”提醒：
1. 泰恩康近30日內北向資金持股量減少55.15萬股，占流通股比例減少0.20%；
2. 近30日內無機構對泰恩康進行調研。
更多個(ge)股趨勢信(xin)息，請搜索微(wei)信(xin)公眾號(hao)“道達號(hao)”，回復“查詢(xun)”，領取免費查詢(xun)權限！

每(mei)經頭條（nbdtoutiao）——

(記者 蔡鼎)

免責(ze)聲明(ming)：本文內容(rong)與數據僅供參(can)考，不(bu)構成投資建議，使用前請(qing)核實。據此操作，風險自擔(dan)。